PL2331118T3 - Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka - Google Patents

Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka

Info

Publication number: PL2331118T3
Authority: PL; Poland
Prior art keywords: cancer; gbm; glioma; tumor; types
Prior art date: 2008-10-01

Application number

PL09778749T

Other languages

English (en)

Inventor

Oliver Schoor

Norbert Hilf

Toni Weinschenk

Claudia Trautwein

Steffen Walter

Harpreet Singh

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-01

Filing date

2009-09-28

Publication date

2017-05-31

2009-09-28 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2017-05-31 Publication of PL2331118T3 publication Critical patent/PL2331118T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
- A61M5/002—Packages specially adapted therefor, e.g. packages for syringes or needles or kits for diabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Mycology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)

PL09778749T 2008-10-01 2009-09-28 Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka PL2331118T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP20080017305 EP2172211B1 (en)	2008-10-01	2008-10-01	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US10597008P	2008-10-16	2008-10-16
EP09778749.3A EP2331118B1 (en)	2008-10-01	2009-09-28	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers

Publications (1)

Publication Number	Publication Date
PL2331118T3 true PL2331118T3 (pl)	2017-05-31

Family

ID=40342382

Family Applications (12)

Application Number	Title	Priority Date	Filing Date
PL08017305T PL2172211T3 (pl)	2008-10-01	2008-10-01	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
PL08017921T PL2172212T3 (pl)	2008-10-01	2008-10-13	Nowatorska immunoterapia przeciwko szeregowi guzów włączając guzy neuronowe i guzy mózgu
PL16179226T PL3120870T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179163T PL3106175T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL09778750.1T PL2341927T3 (pl)	2008-10-01	2009-09-28	Kompozycja obejmująca peptydy związane z nowotworem i szczepionka do leczenia glejaka i innych nowotworów
PL09778749T PL2331118T3 (pl)	2008-10-01	2009-09-28	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
PL16179192T PL3120869T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179241T PL3111952T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179214T PL3124043T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16165070T PL3069728T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179174T PL3120868T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179169T PL3132801T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu

Family Applications Before (5)

Application Number	Title	Priority Date	Filing Date
PL08017305T PL2172211T3 (pl)	2008-10-01	2008-10-01	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
PL08017921T PL2172212T3 (pl)	2008-10-01	2008-10-13	Nowatorska immunoterapia przeciwko szeregowi guzów włączając guzy neuronowe i guzy mózgu
PL16179226T PL3120870T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179163T PL3106175T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL09778750.1T PL2341927T3 (pl)	2008-10-01	2009-09-28	Kompozycja obejmująca peptydy związane z nowotworem i szczepionka do leczenia glejaka i innych nowotworów

Family Applications After (6)

Application Number	Title	Priority Date	Filing Date
PL16179192T PL3120869T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179241T PL3111952T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179214T PL3124043T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16165070T PL3069728T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym guzów neuronalnych i guzów mózgu
PL16179174T PL3120868T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu
PL16179169T PL3132801T3 (pl)	2008-10-01	2009-09-28	Nowa immunoterapia względem wielu nowotworów, w tym nowotworów neuronów i mózgu

Country Status (24)

Country	Link
US (20)	US8119139B2 (pl)
EP (12)	EP2172211B1 (pl)
JP (10)	JP5855940B2 (pl)
KR (6)	KR20220058655A (pl)
CN (3)	CN102170901B (pl)
AU (2)	AU2009300088B2 (pl)
BR (2)	BRPI0920791B8 (pl)
CA (9)	CA2936887C (pl)
CY (11)	CY1116302T1 (pl)
DK (12)	DK2172211T3 (pl)
EA (3)	EA023013B1 (pl)
ES (12)	ES2536465T3 (pl)
HR (12)	HRP20201025T8 (pl)
HU (11)	HUE031030T2 (pl)
LT (10)	LT2172212T (pl)
MX (3)	MX2011003539A (pl)
NZ (4)	NZ624533A (pl)
PL (12)	PL2172211T3 (pl)
PT (12)	PT2172211E (pl)
RS (12)	RS53782B1 (pl)
SI (12)	SI2172211T1 (pl)
TR (2)	TR201900809T4 (pl)
UA (3)	UA103202C2 (pl)
WO (2)	WO2010037514A2 (pl)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8435507B2 (en)	2004-08-19	2013-05-07	University Of Maryland	Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
WO2006034334A2 (en)	2004-09-21	2006-03-30	University Of Pittsburgh Of The Commonwealth System Of Higher Education	Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
RS54204B1 (sr) *	2007-07-27	2015-12-31	Immatics Biotechnologies Gmbh	Nova imunoterapija protiv tumora mozga
EP2113253B1 (en)	2008-04-30	2010-03-31	Immatics Biotechnologies GmbH	Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
PT2119726E (pt) *	2008-05-14	2015-03-30	Immatics Biotechnologies Gmbh	Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano
ES2536465T3 (es) *	2008-10-01	2015-05-25	Immatics Biotechnologies Gmbh	Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
TW201124530A (en) *	2009-12-01	2011-07-16	Oncotherapy Science Inc	IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) *	2009-12-15	2013-03-19	Theravac Pharmaceuticals Ab	Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
AU2015200751B2 (en) *	2010-03-19	2016-11-10	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012027379A2 (en) *	2010-08-24	2012-03-01	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
WO2012075490A2 (en) *	2010-12-03	2012-06-07	Duke University	Anti-podoplanin antibodies and methods of use
SG191154A1 (en) *	2010-12-14	2013-07-31	Immatics Biotechnologies Gmbh	Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2013052158A2 (en) *	2011-04-26	2013-04-11	William Marsh Rice University	Targeted nanovectors and their use for treatment of brain tumors
CN104023749B (zh)	2011-09-14	2019-12-17	西北大学	能穿过血脑屏障的纳米缀合物
GB201120779D0 (en) *	2011-12-02	2012-01-11	Immodulon Therapeutics Ltd	Cancer therapy
CN115778934A (zh)	2012-01-20	2023-03-14	德玛公司	经取代的己糖醇类用于治疗恶性肿瘤的用途
US10704021B2 (en)	2012-03-15	2020-07-07	Flodesign Sonics, Inc.	Acoustic perfusion devices
CN103372217B (zh) *	2012-04-28	2014-12-10	中国科学院深圳先进技术研究院	聚合物纳米载体制剂及其制备方法和应用
WO2013173411A1 (en)	2012-05-16	2013-11-21	Stemline Therapeutics, Inc	Cancer stem cell targeted cancer vaccines
CN112587671A (zh) *	2012-07-18	2021-04-02	博笛生物科技有限公司	癌症的靶向免疫治疗
ES2900004T3 (es)	2013-08-05	2022-03-15	Immatics Biotechnologies Gmbh	Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
TWI714869B (zh) *	2013-08-05	2021-01-01	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) *	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) *	2013-11-04	2020-02-03	Immatics Biotechnologies Gmbh	Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) *	2013-12-04	2017-07-21	苏州中赢医疗科技有限公司	一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en)	2013-12-20	2014-02-05	Immodulon Therapeutics Ltd	Cancer therapy
CN105939767B (zh)	2014-01-08	2018-04-06	弗洛设计声能学公司	具有双声电泳腔的声电泳装置
KR101503341B1 (ko)	2014-03-12	2015-03-18	국립암센터	자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2015164759A2 (en)	2014-04-25	2015-10-29	Bluebird Bio, Inc.	Mnd promoter chimeric antigen receptors
CN106456670B (zh)	2014-04-25	2020-01-07	蓝鸟生物公司	制备过继性细胞疗法的改善方法
JP6613526B2 (ja) *	2014-05-28	2019-12-04	学校法人東京女子医科大学	膠芽腫の予測方法
JP2015227292A (ja) *	2014-05-30	2015-12-17	国立大学法人高知大学	膵がん細胞浸潤転移抑制ワクチン
RS61406B1 (sr) *	2014-06-06	2021-03-31	Bluebird Bio Inc	Poboljšane kompozicije t ćelija
JP6366379B2 (ja) *	2014-06-20	2018-08-01	キヤノン株式会社	被検体情報取得装置
EP3172231B1 (en)	2014-07-24	2021-05-05	Bluebird Bio, Inc.	Bcma chimeric antigen receptors
MX386458B (es) *	2014-11-06	2025-03-18	Ose Immunotherapeutics	Composiciones de péptidos t inmuno-terapéuticas para usarse en el tratamiento de metástasis cerebrales.
US10383929B2 (en)	2014-12-12	2019-08-20	Bluebird Bio, Inc.	BCMA chimeric antigen receptors
GB201501017D0 (en) *	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA50819A (fr) *	2014-12-23	2021-04-07	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
GB201423361D0 (en) *	2014-12-30	2015-02-11	Immatics Biotechnologies Gmbh	Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
CR20210232A (es)	2015-03-17	2022-06-24	Immatics Biotechnologies Gmbh	NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419)
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11708572B2 (en)	2015-04-29	2023-07-25	Flodesign Sonics, Inc.	Acoustic cell separation techniques and processes
US11377651B2 (en)	2016-10-19	2022-07-05	Flodesign Sonics, Inc.	Cell therapy processes utilizing acoustophoresis
CR20230131A (es) *	2015-05-06	2023-06-23	Immatics Biotechnologies Gmbh	NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS Y DE SOPORTES PARA LA INMUNOTERAPIA CONTRA EL CARCINOMA COLORRECTAL Y OTROS TIPOS DE CÁNCER (Divisional Exp. 2017-0497)
GB201507719D0 (en) *	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
US11305002B2 (en)	2015-06-09	2022-04-19	The Board Of Regents Of The University Of Oklahoma	Compositions and treatments for Haemophilus influenzae
WO2016207646A1 (en)	2015-06-24	2016-12-29	Immodulon Therapeutics Limited	A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en)	2015-07-01	2024-01-01	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PT3319985T (pt) *	2015-07-06	2021-01-06	Immatics Biotechnologies Gmbh	Novos péptidos e combinação de péptidos para uso em imunoterapia do cancro do esófago e outros cancros
GB201512369D0 (en) *	2015-07-15	2015-08-19	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) *	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL292864A (en)	2015-08-28	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
GB201515321D0 (en)	2015-08-28	2015-10-14	Immatics Biotechnologies Gmbh	Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
EP3344276B1 (en)	2015-09-03	2020-04-22	The Board of Regents of the University of Oklahoma	Peptide inhibitors of clostridium difficile tcdb toxin
US12098387B2 (en)	2015-10-19	2024-09-24	University Of Maryland, Baltimore	Methods for generating engineered human primary blood dendritic cell lines
WO2017099712A1 (en)	2015-12-07	2017-06-15	Bluebird Bio, Inc.	Improved t cell compositions
GB201521746D0 (en) *	2015-12-10	2016-01-27	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
MY196837A (en) *	2015-12-11	2023-05-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
JP7114477B2 (ja)	2015-12-16	2022-08-08	グリットストーンバイオインコーポレイテッド	新生抗原の特定、製造、および使用
WO2017123996A1 (en)	2016-01-15	2017-07-20	City Of Hope	Targeting glioblastoma stem cells through the tlx-tet3 axis
PE20181583A1 (es) *	2016-03-01	2018-10-04	Immatics Biotechnologies Gmbh	Peptido recombinante derivado de la proteina duoxa2
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en)	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
CN105664134B (zh) *	2016-03-13	2019-04-26	浙江药苑生物科技有限公司	一种用于治疗骨癌的药物组合物
GB201604490D0 (en) *	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides combination of peptides for use in immunotherapy against cancers
GB201604494D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
HRP20221375T1 (hr)	2016-03-16	2023-01-06	Immatics Biotechnologies Gmbh	Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka
EP4357454A3 (en) *	2016-03-16	2024-07-24	Immatics Biotechnologies GmbH	Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG10202110335PA (en) *	2016-04-06	2021-10-28	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
US11214789B2 (en)	2016-05-03	2022-01-04	Flodesign Sonics, Inc.	Concentration and washing of particles with acoustics
WO2017194170A1 (en) *	2016-05-13	2017-11-16	Biontech Rna Pharmaceuticals Gmbh	Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko)	2016-06-30	2018-07-25	영남대학교 산학협력단	아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
CN110022889B (zh) *	2016-10-03	2024-05-10	渥太华医院研究所	用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法
MX2019005277A (es)	2016-11-04	2019-09-27	Bluebird Bio Inc	Composiciones de celulas t con car anti-bcma.
EP4317432A3 (en)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T cell receptors with improved pairing
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
CN110325205B (zh)	2016-12-22	2023-08-15	库尔生物制药有限公司	T细胞调节性多聚体多肽及其使用方法
US10174122B2 (en)	2017-01-06	2019-01-08	Eutilex Co., Ltd.	Anti-human 4-1BB antibodies and uses thereof
GB201702863D0 (en) *	2017-02-22	2017-04-05	Evox Therapeutics Ltd	Improved loading of EVs with therapeutic proteins
WO2018160498A1 (en) *	2017-02-28	2018-09-07	Lyten, Inc.	Mixed allotrope particulate carbon films and carbon fiber mats
KR102945203B1 (ko) *	2017-05-08	2026-03-31	시애틀 프로젝트 코포레이션	알파바이러스 신생항원 벡터
CN107034305A (zh) *	2017-06-19	2017-08-11	上海市第十人民医院	恶性胶质瘤的一种诊断标志物
CN107058596A (zh) *	2017-06-19	2017-08-18	上海市第十人民医院	一种与恶性胶质瘤诊断相关的标志物及其应用
CN111465989B (zh)	2017-10-10	2024-06-25	磨石生物公司	使用热点进行的新抗原鉴别
AU2018373154B2 (en)	2017-11-22	2025-08-07	Seattle Project Corp.	Reducing junction epitope presentation for neoantigens
CN111344402A (zh) *	2017-12-14	2020-06-26	Ezy生物科技有限公司	受试者特异性肿瘤抑制细胞及其用途
CN114900773A (zh)	2017-12-14	2022-08-12	弗洛设计声能学公司	声泳系统及其操作方法、控制声换能器及声学系统的方法
ES2935702T3 (es) *	2018-04-11	2023-03-09	Enterome S A	Péptidos antigénicos para la prevención y el tratamiento del cáncer
CN108715832B (zh) *	2018-06-01	2020-11-10	段海峰	一种抑制肿瘤生长的间充质干细胞及制备方法和应用
JP2021530218A (ja)	2018-07-11	2021-11-11	ザブリガムアンドウィメンズホスピタルインコーポレイテッドThe Brigham and Women’s Hospital, Inc.	血液脳関門を超える薬剤の送達のための方法および組成物
KR20210090650A (ko)	2018-11-07	2021-07-20	그릿스톤 바이오, 인코포레이티드	알파바이러스 신생항원 벡터 및 인터페론 억제제
WO2020110154A1 (en) *	2018-11-30	2020-06-04	Bharat Biotech International Limited	A chimeric therapeutic vaccine
RU2706554C1 (ru) *	2018-12-13	2019-11-19	Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ	Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) *	2019-02-22	2021-09-17	上海尚泰生物技术有限公司	一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
MX2021011848A (es)	2019-03-29	2021-10-22	Intervet Int Bv	Estabilizacion de bacterias mollicutes vivas en una composicion liquida.
US12582726B1 (en)	2019-04-05	2026-03-24	Earli Inc.	Synthetic cancer-specific promoters
EP3946470A4 (en) *	2019-04-05	2023-05-31	Earli Inc.	IMPROVED METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS
CN114207675A (zh)	2019-05-28	2022-03-18	佩治人工智能公司	用于数字病理学的用于处理图像以针对所处理的图像制备载片的系统和方法
SG11202113187WA (en)	2019-05-30	2021-12-30	Gritstone Bio Inc	Modified adenoviruses
CN110579457B (zh) *	2019-09-20	2021-11-02	郑州大学第一附属医院	波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) *	2019-11-18	2022-06-24	杨小骏	一种抑制胶质瘤的短肽及其应用
CA3167290A1 (en) *	2020-01-10	2021-07-15	The Brigham And Women's Hospital, Inc.	Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
US20230055337A1 (en) *	2020-02-24	2023-02-23	The Regents Of The University Of California	Use of brain-specific antigens to home, block and deliver cell-based treatments to the brain
CN113318225B (zh) *	2020-02-28	2024-01-19	无锡派列博生物医药科技有限公司	肿瘤免疫增强剂及其制法和应用
CN113621023A (zh) *	2020-03-18	2021-11-09	北京鼎成肽源生物技术有限公司	一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
JP2023521966A (ja) *	2020-03-31	2023-05-26	ウォーキングフィッシュセラピューティクス，インコーポレイテッド	改変ｂ細胞及びその使用方法
EP4127188A4 (en)	2020-03-31	2024-08-21	Walking Fish Therapeutics	MODIFIED B CELLS AND METHODS OF USE THEREOF
IL296209A (en)	2020-05-12	2022-11-01	Cue Biopharma Inc	Multimeric t-cell modulatory polypeptides and methods of using them
US20230279424A1 (en) *	2020-05-26	2023-09-07	University Health Network	Combination cytokines for methods and compositions for treating cancer
IL300026A (en)	2020-08-06	2023-03-01	Gritstone Bio Inc	Multiepitope vaccine cassettes
KR102711471B1 (ko)	2020-08-14	2024-09-30	서울대학교산학협력단	B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
US20220062406A1 (en) *	2020-08-28	2022-03-03	Torigen Pharmaceuticals, Inc.	Immune memory enhanced preparations and uses thereof
CN116710115A (zh)	2020-11-20	2023-09-05	思维疗法股份有限公司	用于优化的肽疫苗的组合物和方法
US11421015B2 (en)	2020-12-07	2022-08-23	Think Therapeutics, Inc.	Method of compact peptide vaccines using residue optimization
US11058751B1 (en)	2020-11-20	2021-07-13	Think Therapeutics, Inc.	Compositions for optimized RAS peptide vaccines
JP2024509576A (ja) *	2021-03-09	2024-03-04	ボストンジーンコーポレイション	明細胞腎細胞がんを有する患者における治療に対する応答の予測
US11464842B1 (en)	2021-04-28	2022-10-11	Think Therapeutics, Inc.	Compositions and method for optimized peptide vaccines using residue optimization
US20250235517A1 (en) *	2022-03-30	2025-07-24	Iogenetics, Llc	Tumor-associated antigens in brain tumors
PL441229A1 (pl) *	2022-05-19	2023-11-20	Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk	Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102907303B1 (ko)	2024-12-23	2025-12-31	전남대학교산학협력단	다중 분기 잠재 확산 모델 기반 초음파 유도 조직 검사 바늘의 경로 및 위치 실시간 검출 장치, 방법
CN120272531B (zh) *	2025-06-10	2025-08-19	鼐济医药科技(杭州)有限公司	一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en)	1978-12-22	1990-04-30	Biogen Nv	Process for obtaining recombinant dnk molecules
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en)	1986-06-27	1990-01-30	The Administrators Of The Tulane Educational Fund	Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) *	1988-04-12	1994-08-16	Massachusetts Institute Of Technology	DNA encoding nestin protein
KR100235089B1 (en)	1992-05-14	1999-12-15	Mitsui Chemicals Inc	Ptp or blister packaging articles and packaging material therefor
GB2267257A (en)	1992-05-14	1993-12-01	Ford Motor Co	A vehicle load compartment liner.
CA2163032C (en)	1993-06-03	2001-02-06	John Landon	Antibody fragments in therapy
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en)	1996-01-17	2004-10-19	Imperial College Innovations Limited	Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en)	1996-03-11	1998-12-15	Duke University	Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
TW575583B (en) *	1996-04-24	2004-02-11	Akzo Nobel Nv	Novel peptides suitable for use in antigen specific immunosuppressive therapy
CA2262007A1 (en) *	1996-07-22	1998-01-29	The Rockefeller University	Env-glycoprotein vaccine for protection of htlv-i and -ii infection
WO1998031797A1 (en)	1997-01-15	1998-07-23	Zymogenetics, Inc.	Zppar6, human tailless nuclear hormone receptor (tlx receptor)
CA2243984A1 (en) *	1997-02-13	1998-08-20	Smithkline Beecham P.L.C.	Neural cell adhesion molecule splicing variants
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999028349A2 (en) *	1997-12-02	1999-06-10	Medarex, Inc.	CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US7258860B2 (en) *	1998-03-18	2007-08-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AU3762699A (en) *	1998-04-27	1999-11-16	Pacific Northwest Cancer Foundation	(nr-cam) gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US6960651B2 (en) *	1999-06-29	2005-11-01	Millennium Pharmaceuticals, Inc.	TANGO 332 polypeptides
US20020042386A1 (en) *	2000-01-31	2002-04-11	Rosen Craig A.	Nucleic acids, proteins, and antibodies
WO2001055448A1 (en) *	2000-01-31	2001-08-02	Human Genome Sciences, Inc.	Nucleic acids, proteins, and antibodies
US20040191260A1 (en)	2003-03-26	2004-09-30	Technion Research & Development Foundation Ltd.	Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1294748B1 (en)	2000-03-27	2010-06-30	Technion Research and Development of Foundation, Ltd.	Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
EP1317275A1 (de) *	2000-09-06	2003-06-11	Müller, Friederike	Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
EP1356048A2 (en) *	2000-12-04	2003-10-29	Argonex Pharmaceuticals	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en)	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046767A2 (en) *	2000-12-08	2002-06-13	Oxford Glycosciences (Uk) Ltd.	Diagnosis and treatment of alzheimer's disease
US20030109434A1 (en) *	2001-03-19	2003-06-12	Corixa Corporation	Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) *	2001-11-30	2003-05-30	Christopher Gillberg	Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en)	2001-12-21	2003-07-08	Kloeckner Pentaplast Of America, Inc.	Three part high moisture barrier for packages
US7892559B2 (en) *	2002-01-30	2011-02-22	Survac Aps	Survivin-derived peptides and use thereof
US6992176B2 (en) *	2002-02-13	2006-01-31	Technion Research & Development Foundation Ltd.	Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en)	2002-02-20	2003-09-09	Dyax Corporation	Mhc-peptide complex binding ligands
WO2004015390A2 (en) *	2002-08-09	2004-02-19	Applera Corporation	Lung cancer target proteins and use thereof
JP4721633B2 (ja) *	2002-10-11	2011-07-13	財団法人癌研究会	血小板凝集促進活性を有する物質
JP2006516258A (ja) *	2002-12-27	2006-06-29	シェンジェンシチンファユアンシンシェンウイヤオカジヨウシャンゴンシ	ワクチンおよび抗腫瘍ワクチンを調製する方法
EP1615552A4 (en)	2003-04-04	2006-11-29	Pharmacyclics Inc	SAPPHYRINE AND ITS USES
US7273980B2 (en)	2004-01-13	2007-09-25	Wardle Scott A	Position and velocity transducer using a phonograph disc and turntable
EP1712620A4 (en) *	2004-01-23	2008-05-28	Greenpeptide Co Ltd	EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE
DE102004026135A1 (de) *	2004-05-25	2006-01-05	Immatics Biotechnologies Gmbh	An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) *	2004-08-27	2008-11-13	Northeastern University	Comprehensive Characterization Of Complex Proteins At Trace Levels
EP1642905B1 (en) *	2004-10-02	2009-01-21	Immatics Biotechnologies GmbH	Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
CN101072875B (zh) *	2004-12-07	2011-05-18	东丽株式会社	新型癌抗原肽及其用途
KR100809410B1 (ko) *	2005-07-06	2008-03-05	주식회사 브레인가드	줄기세포 분화 유도용 조성물 및 그의 용도
SI1760089T1 (sl) *	2005-09-05	2009-12-31	Immatics Biotechnologies Gmbh	S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
DE602005020046D1 (de)	2005-09-05	2010-04-29	Immatics Biotechnologies Gmbh	Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
WO2007047796A2 (en)	2005-10-17	2007-04-26	Institute For Systems Biology	Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) *	2005-12-06	2007-10-25	Keller Lorraine H	Immunogens in cancer stem cells
WO2007072494A1 (en)	2005-12-23	2007-06-28	Naik Praful Ramchandra	Metallized packaging blister container
CA2665816C (en) *	2006-09-21	2016-07-12	Vaxil Biotherapeutics Ltd.	Antigen specific multi epitope vaccines
CA2700573C (en) *	2006-09-26	2016-11-22	Cedars-Sinai Medical Center	Cancer stem cell antigen vaccines and methods
CA2679743A1 (en) *	2007-03-06	2008-09-12	Barry G. Arnason	Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2009125394A1 (en) *	2008-04-09	2009-10-15	Technion Research & Development Foundation Ltd.	Anti human immunodeficiency antibodies and uses thereof
EP2113253B1 (en) *	2008-04-30	2010-03-31	Immatics Biotechnologies GmbH	Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines
KR101184869B1 (ko) *	2008-04-24	2012-09-20	이매틱스 바이오테크놀로지스 게엠베하	백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
ES2536465T3 (es)	2008-10-01	2015-05-25	Immatics Biotechnologies Gmbh	Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
GB201004551D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en)	2010-12-15	2011-01-26	Immatics Biotechnologies Gmbh	Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
UA123820C2 (uk) *	2014-05-28	2021-06-09	Ноно Інк.	Хлоридна сіль пептиду tat-nr2b9c
MA43477A1 (fr)	2016-04-21	2019-05-31	Immatics Biotechnologies Gmbh	Immunothérapie contre le mélanome et d'autres cancers
CN111315769A (zh) *	2017-09-06	2020-06-19	加州理工学院	信号传导和抗原呈递双功能受体(sabr)

2008
- 2008-10-01 ES ES08017305.7T patent/ES2536465T3/es active Active
- 2008-10-01 RS RS20150094A patent/RS53782B1/sr unknown
- 2008-10-01 PT PT80173057T patent/PT2172211E/pt unknown
- 2008-10-01 EP EP20080017305 patent/EP2172211B1/en active Active
- 2008-10-01 SI SI200831373T patent/SI2172211T1/sl unknown
- 2008-10-01 DK DK08017305T patent/DK2172211T3/en active
- 2008-10-01 PL PL08017305T patent/PL2172211T3/pl unknown
- 2008-10-13 ES ES08017921.1T patent/ES2607460T3/es active Active
- 2008-10-13 RS RS20161019A patent/RS55543B1/sr unknown
- 2008-10-13 HU HUE08017921A patent/HUE031030T2/en unknown
- 2008-10-13 PL PL08017921T patent/PL2172212T3/pl unknown
- 2008-10-13 PT PT80179211T patent/PT2172212T/pt unknown
- 2008-10-13 SI SI200831695A patent/SI2172212T1/sl unknown
- 2008-10-13 LT LTEP08017921.1T patent/LT2172212T/lt unknown
- 2008-10-13 DK DK08017921.1T patent/DK2172212T3/da active
- 2008-10-13 EP EP08017921.1A patent/EP2172212B1/en active Active
2009
- 2009-09-28 SI SI200931902T patent/SI3111952T1/sl unknown
- 2009-09-28 DK DK16179214.8T patent/DK3124043T3/da active
- 2009-09-28 PL PL16179226T patent/PL3120870T3/pl unknown
- 2009-09-28 ES ES16179169T patent/ES2770090T3/es active Active
- 2009-09-28 LT LTEP16179174.4T patent/LT3120868T/lt unknown
- 2009-09-28 PL PL16179163T patent/PL3106175T3/pl unknown
- 2009-09-28 EP EP16179192.6A patent/EP3120869B1/en active Active
- 2009-09-28 CA CA2936887A patent/CA2936887C/en active Active
- 2009-09-28 KR KR1020227013879A patent/KR20220058655A/ko not_active Ceased
- 2009-09-28 DK DK16179169.4T patent/DK3132801T3/da active
- 2009-09-28 RS RS20161160A patent/RS55531B1/sr unknown
- 2009-09-28 LT LTEP16165070.0T patent/LT3069728T/lt unknown
- 2009-09-28 EP EP16179241.1A patent/EP3111952B1/en active Active
- 2009-09-28 SI SI200932064T patent/SI3120870T1/sl unknown
- 2009-09-28 RS RS20200691A patent/RS60381B1/sr unknown
- 2009-09-28 HU HUE16165070A patent/HUE041446T2/hu unknown
- 2009-09-28 LT LTEP16179169.4T patent/LT3132801T/lt unknown
- 2009-09-28 EA EA201100586A patent/EA023013B1/ru unknown
- 2009-09-28 CA CA2936870A patent/CA2936870C/en active Active
- 2009-09-28 PT PT161791694T patent/PT3132801T/pt unknown
- 2009-09-28 WO PCT/EP2009/006980 patent/WO2010037514A2/en not_active Ceased
- 2009-09-28 DK DK09778750.1T patent/DK2341927T3/en active
- 2009-09-28 KR KR1020207019579A patent/KR102392070B1/ko not_active Expired - Fee Related
- 2009-09-28 EP EP09778749.3A patent/EP2331118B1/en active Active
- 2009-09-28 HU HUE16179169A patent/HUE047365T2/hu unknown
- 2009-09-28 CA CA2739387A patent/CA2739387C/en active Active
- 2009-09-28 CN CN200980139420.5A patent/CN102170901B/zh not_active Expired - Fee Related
- 2009-09-28 CN CN200980139419.2A patent/CN102170900B/zh active Active
- 2009-09-28 CA CA2936868A patent/CA2936868C/en active Active
- 2009-09-28 UA UAA201103612A patent/UA103202C2/ru unknown
- 2009-09-28 HU HUE09778750A patent/HUE029360T2/en unknown
- 2009-09-28 PT PT97787493T patent/PT2331118T/pt unknown
- 2009-09-28 RS RS20200085A patent/RS60006B1/sr unknown
- 2009-09-28 NZ NZ624533A patent/NZ624533A/en not_active IP Right Cessation
- 2009-09-28 PL PL09778750.1T patent/PL2341927T3/pl unknown
- 2009-09-28 HR HRP20201025TT patent/HRP20201025T8/hr unknown
- 2009-09-28 EP EP16179163.7A patent/EP3106175B1/en active Active
- 2009-09-28 RS RS20200973A patent/RS60656B1/sr unknown
- 2009-09-28 EP EP09778750.1A patent/EP2341927B1/en active Active
- 2009-09-28 HU HUE16179241A patent/HUE042115T2/hu unknown
- 2009-09-28 KR KR1020117010000A patent/KR101687840B1/ko not_active Expired - Fee Related
- 2009-09-28 RS RS20200693A patent/RS60386B1/sr unknown
- 2009-09-28 AU AU2009300088A patent/AU2009300088B2/en not_active Ceased
- 2009-09-28 DK DK16179192.6T patent/DK3120869T3/da active
- 2009-09-28 RS RS20181585A patent/RS58229B1/sr unknown
- 2009-09-28 SI SI200932083T patent/SI3120869T1/sl unknown
- 2009-09-28 AU AU2009300087A patent/AU2009300087B2/en not_active Ceased
- 2009-09-28 DK DK16179226.2T patent/DK3120870T3/da active
- 2009-09-28 UA UAA201103611A patent/UA110599C2/uk unknown
- 2009-09-28 ES ES16179214T patent/ES2788129T3/es active Active
- 2009-09-28 JP JP2011529472A patent/JP5855940B2/ja not_active Expired - Fee Related
- 2009-09-28 KR KR1020117010003A patent/KR101756488B1/ko not_active Expired - Fee Related
- 2009-09-28 NZ NZ591855A patent/NZ591855A/xx not_active IP Right Cessation
- 2009-09-28 DK DK16179163.7T patent/DK3106175T3/da active
- 2009-09-28 HR HRP20170115TT patent/HRP20170115T1/hr unknown
- 2009-09-28 LT LTEP16179192.6T patent/LT3120869T/lt unknown
- 2009-09-28 RS RS20200512A patent/RS60338B1/sr unknown
- 2009-09-28 EP EP16179214.8A patent/EP3124043B1/en active Active
- 2009-09-28 SI SI200931921T patent/SI3069728T1/sl unknown
- 2009-09-28 CA CA2936924A patent/CA2936924C/en active Active
- 2009-09-28 KR KR1020187021349A patent/KR102133402B1/ko not_active Expired - Fee Related
- 2009-09-28 NZ NZ603016A patent/NZ603016A/en not_active IP Right Cessation
- 2009-09-28 DK DK16165070.0T patent/DK3069728T3/en active
- 2009-09-28 DK DK16179241.1T patent/DK3111952T3/en active
- 2009-09-28 PL PL09778749T patent/PL2331118T3/pl unknown
- 2009-09-28 RS RS20160553A patent/RS55043B1/sr unknown
- 2009-09-28 ES ES16165070T patent/ES2710608T3/es active Active
- 2009-09-28 PL PL16179192T patent/PL3120869T3/pl unknown
- 2009-09-28 MX MX2011003539A patent/MX2011003539A/es active IP Right Grant
- 2009-09-28 HU HUE16179192A patent/HUE050428T2/hu unknown
- 2009-09-28 ES ES16179241T patent/ES2708654T3/es active Active
- 2009-09-28 ES ES09778749.3T patent/ES2612466T3/es active Active
- 2009-09-28 MX MX2011003540A patent/MX2011003540A/es active IP Right Grant
- 2009-09-28 PT PT161791926T patent/PT3120869T/pt unknown
- 2009-09-28 BR BRPI0920791A patent/BRPI0920791B8/pt not_active IP Right Cessation
- 2009-09-28 SI SI200931573A patent/SI2331118T1/sl unknown
- 2009-09-28 PT PT161792148T patent/PT3124043T/pt unknown
- 2009-09-28 PT PT161791637T patent/PT3106175T/pt unknown
- 2009-09-28 PL PL16179241T patent/PL3111952T3/pl unknown
- 2009-09-28 WO PCT/EP2009/006979 patent/WO2010037513A1/en not_active Ceased
- 2009-09-28 HU HUE09778749A patent/HUE030296T2/en unknown
- 2009-09-28 SI SI200932056T patent/SI3124043T1/sl unknown
- 2009-09-28 PT PT16179241T patent/PT3111952T/pt unknown
- 2009-09-28 NZ NZ591882A patent/NZ591882A/xx not_active IP Right Cessation
- 2009-09-28 PT PT16165070T patent/PT3069728T/pt unknown
- 2009-09-28 CA CA2936982A patent/CA2936982C/en active Active
- 2009-09-28 UA UAA201500916A patent/UA125277C2/uk unknown
- 2009-09-28 HR HRP20160915TT patent/HRP20160915T1/hr unknown
- 2009-09-28 ES ES16179174T patent/ES2804723T3/es active Active
- 2009-09-28 KR KR1020167022929A patent/KR101883426B1/ko not_active Expired - Fee Related
- 2009-09-28 SI SI200932065T patent/SI3120868T1/sl unknown
- 2009-09-28 PL PL16179214T patent/PL3124043T3/pl unknown
- 2009-09-28 DK DK09778749.3T patent/DK2331118T5/da active
- 2009-09-28 JP JP2011529471A patent/JP5753783B2/ja not_active Expired - Fee Related
- 2009-09-28 EP EP16179174.4A patent/EP3120868B1/en active Active
- 2009-09-28 EP EP16179169.4A patent/EP3132801B1/en active Active
- 2009-09-28 ES ES09778750.1T patent/ES2584245T3/es active Active
- 2009-09-28 EA EA201100587A patent/EA023378B1/ru unknown
- 2009-09-28 BR BRPI0920759A patent/BRPI0920759A2/pt not_active Application Discontinuation
- 2009-09-28 CN CN201610831523.XA patent/CN106986919A/zh active Pending
- 2009-09-28 HU HUE16179163A patent/HUE049367T2/hu unknown
- 2009-09-28 CA CA2936869A patent/CA2936869C/en active Active
- 2009-09-28 PL PL16165070T patent/PL3069728T3/pl unknown
- 2009-09-28 SI SI200931464A patent/SI2341927T1/sl unknown
- 2009-09-28 SI SI200932063T patent/SI3106175T1/sl unknown
- 2009-09-28 HU HUE16179174A patent/HUE049366T2/hu unknown
- 2009-09-28 ES ES16179226T patent/ES2802227T3/es active Active
- 2009-09-28 RS RS20190118A patent/RS58443B1/sr unknown
- 2009-09-28 LT LTEP16179241.1T patent/LT3111952T/lt unknown
- 2009-09-28 PT PT161792262T patent/PT3120870T/pt unknown
- 2009-09-28 MX MX2012012047A patent/MX338294B/es unknown
- 2009-09-28 HU HUE16179226A patent/HUE049364T2/hu unknown
- 2009-09-28 RS RS20200692A patent/RS60385B1/sr unknown
- 2009-09-28 TR TR2019/00809T patent/TR201900809T4/tr unknown
- 2009-09-28 LT LTEP16179226.2T patent/LT3120870T/lt unknown
- 2009-09-28 LT LTEP16179214.8T patent/LT3124043T/lt unknown
- 2009-09-28 CA CA2739384A patent/CA2739384C/en not_active Expired - Fee Related
- 2009-09-28 SI SI200932034T patent/SI3132801T1/sl unknown
- 2009-09-28 LT LTEP09778749.3T patent/LT2331118T/lt unknown
- 2009-09-28 ES ES16179163T patent/ES2802226T3/es active Active
- 2009-09-28 EA EA201401104A patent/EA032437B1/ru unknown
- 2009-09-28 PL PL16179174T patent/PL3120868T3/pl unknown
- 2009-09-28 ES ES16179192T patent/ES2819244T3/es active Active
- 2009-09-28 TR TR2019/00852T patent/TR201900852T4/tr unknown
- 2009-09-28 HU HUE16179214A patent/HUE051030T2/hu unknown
- 2009-09-28 EP EP16179226.2A patent/EP3120870B1/en active Active
- 2009-09-28 PT PT161791744T patent/PT3120868T/pt unknown
- 2009-09-28 LT LTEP16179163.7T patent/LT3106175T/lt unknown
- 2009-09-28 EP EP16165070.0A patent/EP3069728B1/en active Active
- 2009-09-28 PT PT97787501T patent/PT2341927T/pt unknown
- 2009-09-28 CA CA2936920A patent/CA2936920C/en active Active
- 2009-09-28 DK DK16179174.4T patent/DK3120868T3/da active
- 2009-09-28 PL PL16179169T patent/PL3132801T3/pl unknown
- 2009-10-01 US US12/571,776 patent/US8119139B2/en active Active
- 2009-10-01 US US12/571,602 patent/US8318677B2/en active Active
2012
- 2012-01-09 US US13/346,598 patent/US8961985B2/en active Active
- 2012-08-17 US US13/588,206 patent/US8653035B2/en active Active
2013
- 2013-03-15 US US13/841,013 patent/US8895514B2/en active Active
2014
- 2014-06-19 JP JP2014126001A patent/JP5883476B2/ja not_active Expired - Fee Related
- 2014-12-05 US US14/562,156 patent/US10227381B2/en active Active
2015
- 2015-02-12 CY CY20151100139T patent/CY1116302T1/el unknown
- 2015-02-26 HR HRP20150223TT patent/HRP20150223T8/hr unknown
- 2015-10-08 JP JP2015200021A patent/JP6150859B2/ja not_active Expired - Fee Related
2016
- 2016-02-05 JP JP2016021002A patent/JP6214066B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136518A patent/JP6294914B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136516A patent/JP2017029135A/ja active Pending
- 2016-07-11 JP JP2016136515A patent/JP6367266B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136517A patent/JP6294913B2/ja not_active Expired - Fee Related
- 2016-07-11 JP JP2016136519A patent/JP6297632B2/ja not_active Expired - Fee Related
- 2016-08-02 US US15/226,126 patent/US10919931B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,161 patent/US10941181B2/en not_active Expired - Fee Related
- 2016-08-02 US US15/226,081 patent/US10046037B2/en active Active
- 2016-08-02 CY CY20161100759T patent/CY1119744T1/el unknown
- 2016-08-02 US US15/226,038 patent/US10100085B2/en active Active
- 2016-08-02 US US15/226,002 patent/US10047123B2/en active Active
- 2016-08-02 US US15/226,206 patent/US10047124B2/en active Active
- 2016-08-02 US US15/226,098 patent/US10906936B2/en not_active Expired - Fee Related
- 2016-11-15 HR HRP20161504TT patent/HRP20161504T1/hr unknown
2017
- 2017-01-26 CY CY20171100124T patent/CY1118702T1/el unknown
- 2017-06-30 US US15/638,806 patent/US9993540B2/en active Active
2018
- 2018-09-19 US US16/136,008 patent/US20190010190A1/en not_active Abandoned
- 2018-12-18 HR HRP20182151TT patent/HRP20182151T1/hr unknown
- 2018-12-28 CY CY181101403T patent/CY1121098T1/el unknown
2019
- 2019-01-31 HR HRP20190202TT patent/HRP20190202T1/hr unknown
- 2019-02-12 CY CY20191100182T patent/CY1121258T1/el unknown
2020
- 2020-01-23 HR HRP20200110TT patent/HRP20200110T1/hr unknown
- 2020-01-28 CY CY20201100073T patent/CY1122677T1/el unknown
- 2020-05-05 HR HRP20200722TT patent/HRP20200722T1/hr unknown
- 2020-05-15 CY CY20201100449T patent/CY1122913T1/el unknown
- 2020-06-19 HR HRP20200988TT patent/HRP20200988T1/hr unknown
- 2020-06-26 CY CY20201100594T patent/CY1123089T1/el unknown
- 2020-06-26 HR HRP20201015TT patent/HRP20201015T8/hr unknown
- 2020-06-30 CY CY20201100606T patent/CY1123098T1/el unknown
- 2020-07-03 CY CY20201100613T patent/CY1123113T1/el unknown
- 2020-08-06 HR HRP20201228TT patent/HRP20201228T1/hr unknown
- 2020-10-19 CY CY20201100984T patent/CY1123526T1/el unknown
2021
- 2021-04-23 US US17/238,806 patent/US12221493B2/en active Active
- 2021-04-23 US US17/238,840 patent/US11136352B2/en active Active
- 2021-04-23 US US17/238,787 patent/US12234298B2/en active Active
- 2021-07-23 US US17/384,152 patent/US11208434B2/en not_active Expired - Fee Related
2025
- 2025-01-06 US US19/010,602 patent/US20260116918A1/en active Pending

Also Published As

Publication number	Publication date
LT2331118T (lt)	2016-12-27
HRP20200988T1 (hr)	2020-10-16
UA125277C2 (uk)	2022-02-16
US11208434B2 (en)	2021-12-28
CA2936920C (en)	2019-12-03
UA103202C2 (ru)	2013-09-25
JP2016145210A (ja)	2016-08-12
HUE029360T2 (en)	2017-02-28
EP3111952A1 (en)	2017-01-04
PT2172212T (pt)	2016-12-22
NZ591855A (en)	2012-11-30
SI2331118T1 (sl)	2017-01-31
EP3120870B1 (en)	2020-04-01
CA2739384A1 (en)	2010-04-08
CA2936869A1 (en)	2010-04-08
HRP20161504T1 (hr)	2016-12-30
HRP20150223T8 (hr)	2015-07-03
EA023378B1 (ru)	2016-05-31
EA201100587A1 (ru)	2011-10-31
JP5855940B2 (ja)	2016-02-09
PT3069728T (pt)	2019-02-13
US20160376316A1 (en)	2016-12-29
US20160376315A1 (en)	2016-12-29
US10919931B2 (en)	2021-02-16
US20150125478A1 (en)	2015-05-07
KR20220058655A (ko)	2022-05-09
JP5753783B2 (ja)	2015-07-22
US10906936B2 (en)	2021-02-02
LT3132801T (lt)	2020-02-10
US8895514B2 (en)	2014-11-25
MX2011003539A (es)	2011-06-20
CY1123089T1 (el)	2021-10-29
JP6367266B2 (ja)	2018-08-01
CY1123098T1 (el)	2021-10-29
ES2536465T3 (es)	2015-05-25
US20210261614A1 (en)	2021-08-26
AU2009300087B2 (en)	2014-09-04
DK3120868T3 (da)	2020-06-22
EP3120870A1 (en)	2017-01-25
DK2331118T3 (da)	2017-01-09
HUE049367T2 (hu)	2020-09-28
SI3069728T1 (sl)	2019-03-29
PT3120870T (pt)	2020-07-01
NZ591882A (en)	2012-12-21
EA201100586A1 (ru)	2011-10-31
EP3120868B1 (en)	2020-04-08
HK1159526A1 (zh)	2012-08-03
CA2936924C (en)	2019-07-16
SI3120870T1 (sl)	2020-08-31
HK1161106A1 (en)	2012-08-24
EP3120869B1 (en)	2020-07-22
CN102170901A (zh)	2011-08-31
US10047123B2 (en)	2018-08-14
EP2172212B1 (en)	2016-10-05
PL3124043T3 (pl)	2020-07-27
HRP20201015T8 (hr)	2022-01-21
HUE030296T2 (en)	2017-04-28
PT3111952T (pt)	2019-02-05
US10100085B2 (en)	2018-10-16
US20110002963A1 (en)	2011-01-06
JP2012504563A (ja)	2012-02-23
NZ624533A (en)	2015-09-25
CY1123113T1 (el)	2021-10-29
TR201900852T4 (tr)	2019-02-21
HUE031030T2 (en)	2017-06-28
US9993540B2 (en)	2018-06-12
EP2331118A1 (en)	2011-06-15
US20210347822A1 (en)	2021-11-11
HRP20182151T1 (hr)	2019-02-08
US20160376313A1 (en)	2016-12-29
RS53782B1 (sr)	2015-06-30
WO2010037513A1 (en)	2010-04-08
US20190010190A1 (en)	2019-01-10
SI2172212T1 (sl)	2016-12-30
CA2936868C (en)	2019-10-22
EP3069728A1 (en)	2016-09-21
RS60006B1 (sr)	2020-04-30
RS60656B1 (sr)	2020-09-30
CA2936870A1 (en)	2010-04-08
RS55531B1 (sr)	2017-05-31
CY1122913T1 (el)	2021-10-29
HUE047365T2 (hu)	2020-04-28
EP3069728B1 (en)	2018-11-14
SI3132801T1 (sl)	2020-03-31
US10046037B2 (en)	2018-08-14
RS60386B1 (sr)	2020-07-31
CA2936982C (en)	2019-12-03
PT2331118T (pt)	2017-02-06
US20160376314A1 (en)	2016-12-29
SI3106175T1 (sl)	2020-08-31
KR101756488B1 (ko)	2017-07-11
PL3132801T3 (pl)	2020-06-15
LT3111952T (lt)	2018-12-27
RS58443B1 (sr)	2019-04-30
PL3120868T3 (pl)	2020-08-24
DK3124043T3 (da)	2020-05-04
ES2819244T3 (es)	2021-04-15
LT3120869T (lt)	2020-11-10
JP2012504393A (ja)	2012-02-23
PT3106175T (pt)	2020-07-01
LT3124043T (lt)	2020-07-10
US20160376312A1 (en)	2016-12-29
CA2936868A1 (en)	2010-04-08
US10941181B2 (en)	2021-03-09
EA023013B1 (ru)	2016-04-29
US8318677B2 (en)	2012-11-27
MX338294B (es)	2016-04-11
CY1121258T1 (el)	2020-05-29
JP6294914B2 (ja)	2018-03-14
KR101883426B1 (ko)	2018-07-31
PT3132801T (pt)	2020-02-04
EP3106175A1 (en)	2016-12-21
CN102170900B (zh)	2016-10-26
SI3124043T1 (sl)	2020-07-31
EA032437B1 (ru)	2019-05-31
EP2172211B1 (en)	2014-12-03
RS58229B1 (sr)	2019-03-29
EP2172212A3 (en)	2010-04-14
UA110599C2 (uk)	2016-01-25
ES2710608T3 (es)	2019-04-26
MX2011003540A (es)	2011-06-20
ES2708654T3 (es)	2019-04-10
US20210238227A1 (en)	2021-08-05
CY1118702T1 (el)	2017-07-12
PL2341927T3 (pl)	2016-11-30
ES2607460T3 (es)	2017-03-31
EP2341927B1 (en)	2016-05-04
CA2936924A1 (en)	2010-04-08
CA2739387C (en)	2019-10-29
CA2936920A1 (en)	2010-04-08
PT2172211E (pt)	2015-03-09
EP2331118B1 (en)	2016-10-26
KR20180088494A (ko)	2018-08-03
ES2802227T3 (es)	2021-01-18
HRP20190202T1 (hr)	2019-03-22
ES2584245T3 (es)	2016-09-26
SI3120869T1 (sl)	2020-10-30
PL3111952T3 (pl)	2019-04-30
LT3120868T (lt)	2020-08-10
HUE051030T2 (hu)	2021-01-28
CN106986919A (zh)	2017-07-28
EA201401104A1 (ru)	2015-05-29
HRP20150223T1 (hr)	2015-06-05
AU2009300088A1 (en)	2010-04-08
CY1123526T1 (el)	2022-03-24
CY1116302T1 (el)	2017-02-08
HUE041446T2 (hu)	2019-05-28
DK2172211T3 (en)	2015-02-16
CN102170901B (zh)	2015-01-07
HUE049366T2 (hu)	2020-09-28
DK2331118T5 (en)	2017-06-19
ES2802226T3 (es)	2021-01-18
US10227381B2 (en)	2019-03-12
CA2739384C (en)	2017-05-02
BRPI0920791B8 (pt)	2022-02-15
KR20110082155A (ko)	2011-07-18
US10047124B2 (en)	2018-08-14
HRP20170115T1 (hr)	2017-03-24
DK3069728T3 (en)	2019-02-25
KR20110074894A (ko)	2011-07-04
PL3120870T3 (pl)	2020-07-27
EP2172212A2 (en)	2010-04-07
HRP20201025T1 (hr)	2020-12-25
US20130004456A1 (en)	2013-01-03
WO2010037514A2 (en)	2010-04-08
PT2341927T (pt)	2016-08-02
DK3120870T3 (da)	2020-06-22
JP6297632B2 (ja)	2018-03-20
HRP20200722T1 (hr)	2020-10-16
US8961985B2 (en)	2015-02-24
US20170326217A1 (en)	2017-11-16
JP2017023136A (ja)	2017-02-02
WO2010037514A3 (en)	2010-06-03
PT3120869T (pt)	2020-09-22
PL3069728T3 (pl)	2019-05-31
PL3120869T3 (pl)	2021-01-25
US8119139B2 (en)	2012-02-21
DK3120869T3 (da)	2020-08-10
US8653035B2 (en)	2014-02-18
CN102170900A (zh)	2011-08-31
LT3069728T (lt)	2019-02-11
KR102392070B1 (ko)	2022-04-29
PL2172211T3 (pl)	2015-05-29
JP6294913B2 (ja)	2018-03-14
SI2341927T1 (sl)	2016-08-31
JP2014239681A (ja)	2014-12-25
EP2341927A2 (en)	2011-07-13
JP6150859B2 (ja)	2017-06-21
JP2017000148A (ja)	2017-01-05
LT3106175T (lt)	2020-08-10
HUE042115T2 (hu)	2019-06-28
EP3132801A1 (en)	2017-02-22
US12221493B2 (en)	2025-02-11
DK2341927T3 (en)	2016-08-15
CA2936887C (en)	2019-11-12
JP6214066B2 (ja)	2017-10-18
JP2017018102A (ja)	2017-01-26
PL2172212T3 (pl)	2017-04-28
US20100158931A1 (en)	2010-06-24
HUE050428T2 (hu)	2020-12-28
RS60338B1 (sr)	2020-07-31
SI3111952T1 (sl)	2019-01-31
EP3124043A1 (en)	2017-02-01
CA2936887A1 (en)	2010-04-08
AU2009300087A1 (en)	2010-04-08
DK2172212T3 (da)	2016-12-19
NZ603016A (en)	2014-05-30
ES2788129T8 (es)	2020-11-04
CY1121098T1 (el)	2019-12-11
KR102133402B1 (ko)	2020-07-14
CY1122677T1 (el)	2021-03-12
ES2788129T3 (es)	2020-10-20
CA2739387A1 (en)	2010-04-08
US20210253637A1 (en)	2021-08-19
AU2009300088B2 (en)	2014-09-04
DK3106175T3 (da)	2020-06-22
HUE049364T2 (hu)	2020-09-28
EP2172211A1 (en)	2010-04-07
BRPI0920791A2 (pt)	2019-12-10
EP3111952B1 (en)	2018-10-31
HRP20201015T1 (hr)	2020-10-16
HRP20201228T1 (hr)	2021-02-05
EP3132801B1 (en)	2019-10-30
SI3120868T1 (sl)	2020-08-31
JP2017029135A (ja)	2017-02-09
LT2172212T (lt)	2016-11-10
BRPI0920759A2 (pt)	2016-03-08
JP5883476B2 (ja)	2016-03-15
LT3120870T (lt)	2020-08-10
SI2172211T1 (sl)	2015-03-31
HRP20200110T1 (hr)	2020-05-15
RS60381B1 (sr)	2020-07-31
HRP20201025T8 (hr)	2022-01-07
ES2804723T3 (es)	2021-02-09
KR20200085381A (ko)	2020-07-14
TR201900809T4 (tr)	2019-02-21
CA2936982A1 (en)	2010-04-08
JP2016047825A (ja)	2016-04-07
RS55043B1 (sr)	2016-12-30
BRPI0920791B1 (pt)	2022-01-18
CA2936870C (en)	2019-11-26
KR101687840B1 (ko)	2016-12-19
US11136352B2 (en)	2021-10-05
EP3120868A1 (en)	2017-01-25
CY1119744T1 (el)	2018-06-27
US20120141517A1 (en)	2012-06-07
PT3120868T (pt)	2020-07-16
EP3124043B1 (en)	2020-04-29
CA2936869C (en)	2019-08-06
RS60385B1 (sr)	2020-07-31
PT3124043T (pt)	2020-05-12
DK3132801T3 (da)	2020-02-10
RS55543B1 (sr)	2017-05-31
US20260116918A1 (en)	2026-04-30
US20160355550A1 (en)	2016-12-08
KR20160103558A (ko)	2016-09-01
DK3111952T3 (en)	2019-01-28
PL3106175T3 (pl)	2020-08-24
HRP20160915T1 (hr)	2016-10-07
US20160376317A1 (en)	2016-12-29
EP3106175B1 (en)	2020-04-01
US20130309193A1 (en)	2013-11-21
EP3120869A1 (en)	2017-01-25
ES2612466T3 (es)	2017-05-17
US12234298B2 (en)	2025-02-25
JP2017018101A (ja)	2017-01-26
ES2770090T3 (es)	2020-06-30

Publication	Publication Date	Title
DK2331118T3 (da)	2017-01-09	Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
PL2567707T3 (pl)	2017-03-31	Kompozycja peptydów związanych z guzem i pokrewna szczepionka przeciw rakowi
CY1125550T1 (el)	2026-02-25	Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
CY2017019I1 (el)	2018-01-10	Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
IL236516B (en)	2018-05-31	Antibodies and compositions comprising them for treatment of cancer
HUE049886T2 (hu)	2020-10-28	Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra
IL220386B (en)	2020-04-30	Compositions for the liquidation of tumors and uses thereof
ME01814B (me)	2014-09-20	Citotoksični agensi koji sadrže nove derivate tomaimicina i njihova terapeutska primjena
HUE054495T2 (hu)	2021-09-28	Rák kezelésére szolgáló készítmény
CL2013000016A1 (es)	2013-04-19	Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
PL3363456T3 (pl)	2021-05-04	Nowa immunoterapia względem wielu nowotworów, w tym raka układu trawiennego i raka żołądka
PL2547691T3 (pl)	2016-12-30	Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia raka żołądka i innych rodzajów raka
DK3401334T5 (da)	2024-09-23	Monoklonale antistoffer mod claudin-18 til cancerbehandling
IL212633A (en)	2015-03-31	A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
IL251083B (en)	2018-07-31	Compounds and compositions for the treatment of cancer
DK2340042T3 (da)	2014-10-27	Fremgangsmåder og præparater til behandling af cancer
ZA201102969B (en)	2011-12-28	Anti cxcr4 antibodies and their use for the treatment of cancer
HUE036490T2 (hu)	2018-07-30	Tumorok kezelése anti-L1 antitest alkalmazásával
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
EP2328604A4 (en)	2012-03-14	USE OF WNT5-A PEPTIDE DERIVATIVES FOR THE TREATMENT OF MELANOMA AND MAGIC CARCINOMA
HRP20181178T1 (hr)	2018-12-14	Anti-androgeni peptidi i njihova uporaba za terapiju raka
DK2331092T3 (da)	2014-05-19	Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer
BRPI0821100A2 (pt)	2017-05-23	composições e métodos para o tratamento de câncer de bexiga
CL2012000355A1 (es)	2012-08-31	Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc.